

Nov 07, 2017

Platelet activation test (PACT)

PLOS One

DOI

dx.doi.org/10.17504/protocols.io.ki8cuhw

Sven Van Poucke¹, Dana Huskens², Kurt Van der Speeten³, Mark Roest², Bart Lauwereins¹, Ming-Hua Zheng⁴, Seppe Dehaene¹, Joris Penders⁵, Abraham Marcus⁶, Marcus Lancé⁶

¹Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Therapy, ZOL, Genk, Belgium;

HIPACAT



Sven Van Poucke

Department of Anesthesiology, Intensive Care, Emergency Medi...

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN ACCESS



²Synapse Research Institute, Maastricht, The Netherlands.; ³Department of Surgery, ZOL, Genk, Belgium.;

⁴Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.;

⁵Central Diagnostic Laboratory, ZOL, Genk, Belgium;

⁶Department of Anesthesiology, ICU and Perioperative Medicine,HMC, Doha,Qatar



DOI: https://dx.doi.org/10.17504/protocols.io.ki8cuhw

External link: https://doi.org/10.1371/journal.pone.0193657

Protocol Citation: Sven Van Poucke, Dana Huskens, Kurt Van der Speeten, Mark Roest, Bart Lauwereins, Ming-Hua Zheng, Seppe Dehaene, Joris Penders, Abraham Marcus, Marcus Lancé 2017. Platelet activation test (PACT). protocols.io

https://dx.doi.org/10.17504/protocols.io.ki8cuhw

Manuscript citation:

Poucke SV, Huskens D, Speeten KVd, Roest M, Lauwereins B, Zheng M, Dehaene S, Penders J, Marcus A, Lancé M (2018) Thrombin generation and platelet activation in cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy - A prospective cohort study. PLoS ONE 13(6): e0193657. doi: 10.1371/journal.pone.0193657

License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

Created: November 01, 2017

Last Modified: March 14, 2018

Protocol Integer ID: 8512

Keywords: platelet activation, platelet activation test, aggregation potential of platelet, agonist thrombin receptor activator peptide, platelet, thrombin, agonist collagen, pact test, higher agonist dose, blood by the pact, specific agonist, pact, processed blood, receptor, glycoprotein vi, specific insight in the granule release capacity



Abstract

Platelet activation was quantitatively assessed on a randomly selected subgroup of 10 patients (not treated with acetylsalicylic acid) in un-processed blood by the PACT (Platelet activation test, adjusted from Roest 2013). In the original paper, Roest performs the tests at room temperature while in this manuscript, the PACT test is performed at 37°C which requires higher agonist doses. The PACT is based on platelet activation induced by addition of a specific agonist to whole blood and gives specific insight in the granule release capacity and in the aggregation potential of platelets. The test contains three agonists to activate the platelets: (1) the protease activated receptor (PAR-1) agonist thrombin receptor activator peptide (TRAP f.c. 30 μM, SFLLRN, H-2936; Bachem, Germany), (2) the glycoprotein VI (GPVI) agonist collagen-related peptide (CRP f.c. 5 µg/ml, Pro- fessor Farndale, university of Cambridge, UK), and (3) the P2Y12 agonist ADP (f.c. 30 µM, 01897, Sigma-Aldrich, Zwijndrecht, the Netherlands) in HEPES-buffered saline (HBS, 10 mmol/L HEPES, 150 mmol/L NaCl, 1 mmol/L MgSO4, 5 mmol/L KCL, pH 7.4). The reaction mixtures also contain three antibodies directed against GPIb (APC-conjugated CD42b, BD Bioscience), activated αIIbβ3 (FITC-conjugated PAC-1) and P-selectin (PE-conjugated CD62P) purchased from BD Pharmingen (Franklin Lakes, USA). Whole blood was heated at 37°C for 10 min and the tests were performed at 37°C. Whole blood was diluted 1:4 in HEPES-buffered saline and 5 μl of this diluted blood was added to each reaction mixture. Reactions were stopped by adding 250 µl fixation solution (137 mmol/L NaCl, 2.7 mmol/L KCl, 1.12 mmol/L NaH2PO4, 1.15 mmol/L KH2PO4, 10.2 mmol/L Na2HPO4, 4 mmol/L EDTA, 0.5% formaldehyde) after exactly 20 min of incubation at 37°C. Flow cytometry was used to distinguish between platelets and other cells on forward and sideward scatter pattern and by gating on the CD42b positive cells. Fluorescent intensity in the FITC gate and PE gate was selected to determine activated allb\u00e33 and P-selectin density, respectively, and results are expressed as median fluorescent intensity (MFI).

Troubleshooting

